1. 374 Real world prognostic relevance of residual disease and other clinical factors on the progression of disease and death in patients with advanced ovarian cancer in the US. (4th December 2020) Authors: Chase, Dana; Perhanidis, Jessica; Gupta, Divya; Kalilani, Linda; Sansbury, Leah; Woodward, Tatia; González-Martín, Antonio Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 4 Page Start: A74 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial. (September 2022) Authors: Barretina-Ginesta, Maria-Pilar; Monk, Bradley J.; Han, Sileny; Pothuri, Bhavana; Auranen, Annika; Chase, Dana M.; Lorusso, Domenica; Anderson, Charles; Abadie-Lacourtoisie, Sophie; Cloven, Noelle; Braicu, Elena I.; Amit, Amnon; Redondo, Andrés; Shah, Ruchit; Kebede, Nehemiah; Hawkes, Carol; Gupta... Journal: Therapeutic advances in medical oncology Issue: Volume 14(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗